Last reviewed · How we verify
Antibacterial therapies — Competitive Intelligence Brief
marketed
Antibacterial agent (broad class)
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Antibacterial therapies (Antibacterial therapies) — Mansoura University Hospital. Antibacterial therapies work by inhibiting bacterial growth and survival through various mechanisms such as cell wall disruption, protein synthesis inhibition, or DNA damage.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antibacterial therapies TARGET | Antibacterial therapies | Mansoura University Hospital | marketed | Antibacterial agent (broad class) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antibacterial agent (broad class) class)
- Mansoura University Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antibacterial therapies CI watch — RSS
- Antibacterial therapies CI watch — Atom
- Antibacterial therapies CI watch — JSON
- Antibacterial therapies alone — RSS
- Whole Antibacterial agent (broad class) class — RSS
Cite this brief
Drug Landscape (2026). Antibacterial therapies — Competitive Intelligence Brief. https://druglandscape.com/ci/antibacterial-therapies. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab